Get the Stockscreener App
0.5021
10.08%
-0.0563
After Hours:
.49
-0.0121
-2.41%
Hcw Biologics Inc stock is traded at $0.5021, with a volume of 868.76K.
It is down -10.08% in the last 24 hours and up +8.56% over the past month.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
See More
Previous Close:
$0.5584
Open:
$0.5344
24h Volume:
868.76K
Relative Volume:
0.10
Market Cap:
$23.44M
Revenue:
$3.50M
Net Income/Loss:
$-37.33M
P/E Ratio:
-0.9656
EPS:
-0.52
Net Cash Flow:
$-19.15M
1W Performance:
-46.99%
1M Performance:
+8.56%
6M Performance:
-54.77%
1Y Performance:
-51.72%
1-Day Range:
$0.488
$0.56
1-Week Range:
$0.488
$0.8694
52-Week Range:
$0.2761
$2.52
Hcw Biologics Inc Stock (HCWB) Company Profile
Name
Hcw Biologics Inc
Sector
Industry
Phone
954-842-2024
Address
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
0.5021 | 23.44M | 3.50M | -37.33M | -19.15M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Hcw Biologics Inc Stock (HCWB) Latest News
HCW Biologics issues 2.55 million shares to Armistice Capital By Investing.com - Investing.com Nigeria
HCW Biologics issues 2.55 million shares to Armistice Capital - Investing.com India
HCW Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
HCW Biologics takes aim at CD8+ in deal with WY Biotech - The Pharma Letter
HCW Biologics announces pricing of $6.9M registered direct offering, concurrent private placement - MSN
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.13% - MSN
HCW Biologics : Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules Form 8 K - Marketscreener.com
HCW Biologics Expands with New Financial Agreements - TipRanks
HCW Biologics prices $6.9M registered direct offering at $1.03 per share - Yahoo Finance
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLMA Must-Watch This Week! - Marketscreener.com
HCWB stock touches 52-week high at $1.97 amid robust gains - Investing.com Australia
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules - Yahoo Finance
HCW Biologics Secures $6.9M Above-Market Offering with Warrant Coverage | HCWB Stock News - StockTitan
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules - Benzinga
HCW Biologics Announces Pricing of $6.9 Million Registered - GlobeNewswire
Aclaris Therapeutics (ACRS): Strategic Alliance with Biosion Ignites 53% Stock Surge - BP Journal
Sintx Technologies, Inc. (SINT): A Bold Move with Strategic Stock Repurchase Program Boosts Investor Confidence - BP Journal
HCW Biologics Inc. (HCWB): A Strategic Leap with Worldwide Licensing Agreement Sends Stock Up Over 310% - BP Journal
United States shares mixed at close of trade; Dow Jones Industrial Average down 0.13% - Investing.com India
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.13% - Investing.com
U.S. STOCKS Henry Schein Inc, Palantir Technologies, Uber Technologies - XM
Owning 44% shares,institutional owners seem interested in Jamieson Wellness Inc. (TSE:JWEL), - Yahoo Finance
HCW Biologics signs licensing deal with WY Biotech - Investing.com India
Trinity Investors Managing Partner Sanjay Chandra Named One of Dallas Most Influential Leaders on DCEO’s Dallas 500 List - Yahoo Finance
HCW Biologics Shares Surge on License Agreement - MarketWatch
Broward pharma developer inks $7 million deal with Chinese firm - The Business Journals
Enphase Energy Powers Up with US-Made IQ Batteries: Unlocking Bonus Tax Credits - AOL
California logistics company files for Chapter 11 - Yahoo Finance
Crude Oil Rises Sharply; US Homebuilder Sentiment Surges In November - Benzinga
Spirit Airlines Declares Bankruptcy After Failed Merger and Rising Costs - Yahoo Finance
Stock Market News: HCW Biologics increase by 521.18% while CareMax drops by 49.20% during mid day trading - Business Upturn
Ultra low-cost carrier Spirit Airlines files for bankruptcy - Yahoo Finance
U.S. STOCKS Tesla Inc, Palantir Technologies and Super Micro Computer Inc - XM
Nvidia Stock Drops on Report of Snag With Blackwell Chip Servers - Yahoo Finance
Why Is Penny Stock HCW Biologics Surging On Monday? - Yahoo Finance
Dow Falls 100 Points; Brady Posts Upbeat Results - Benzinga
Wall Street Analysts See a 31.3% Upside in Adma Biologics (ADMA): Can the Stock Really Move This High? - Yahoo Finance
Stock market today: CareMax(−41.19%), HCW Biologics(+209.06%) among the most volatile stocks in early trading - Business Upturn
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate - GlobeNewswire
This tiny U.S biotech has made a big deal in China - RagingBull
HCWBHCW Biologics Inc. Latest Stock News & Market Updates - StockTitan
HCW Biologics : Financial Obligation Form 8 K - Marketscreener.com
Kandi Technologies Reports Third Quarter 2024 Financial Results - The Manila Times
HCW Biologics jumps on license agreement for immunotherapeutic product candidate - Seeking Alpha
MedinCell And 2 Other Top Growth Stocks With Strong Insider Ownership - Yahoo Finance
HCW Biologics Inc. and Wy Biotech Announce License Agreement for Immunotherapeutic Product Candidate - Marketscreener.com
Here's What Analysts Are Forecasting For ESCO Technologies Inc. (NYSE:ESE) After Its Yearly Results - Yahoo Finance
dynaCERT Third Quarter 2024 Earnings: CA$0.008 loss per share (vs CA$0.004 loss in 3Q 2023) - Yahoo Finance
Armlogi Holding First Quarter 2025 Earnings: US$0.11 loss per share (vs US$0.069 profit in 1Q 2024) - Yahoo Finance
HCW Biologics Third Quarter 2024 Earnings: US$0.10 loss per share (vs US$0.14 loss in 3Q 2023) - Simply Wall St
Hcw Biologics Inc Stock (HCWB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):